- Home
- SNGX vs XAIR Comparison
SNGX vs XAIR Comparison
Compare SNGX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNGX | XAIR |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 10.1M |
| IPO Year | 2006 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SNGX | XAIR |
|---|---|---|
| Price | $1.23 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $10.00 |
| AVG Volume (30 Days) | 108.6K | ★ 215.1K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | $119,371.00 | ★ $3,705,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $1.02 | $0.15 |
| 52 Week High | $6.23 | $3.78 |
Technical Indicators
Market Signals| Indicator | SNGX | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 36.34 |
| Support Level | $1.19 | $0.67 |
| Resistance Level | $1.22 | $1.25 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 60.27 | 21.07 |
Price Performance
Historical ComparisonAbout SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.